Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices 45783 

Drug Schedule 

N-Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

Nicocodeine (9309) ....................... I 

Nicomorphine (9312) .................... I 

N-Methyl-3-piperidyl benzilate 

(7484).

I 

Noracymethadol (9633) ................ I 

Norlevorphanol (9634) .................. I 

Normethadone (9635) ................... I 

Normorphine (9313) ...................... I 

Norpipanone (9636) ...................... I 

Para-Fluorofentanyl (9812) ........... I 

Parahexyl (7374) .......................... I 

Peyote (7415) ............................... I 

Phenadoxone (9637) .................... I 

Phenampromide (9638) ................ I 

Phenomorphan (9647) .................. I 

Phenoperidine (9641) ................... I 

Pholcodine (9314) ......................... I 

Piritramide (9642) ......................... I 

Proheptazine (9643) ..................... I 

Properidine (9644) ........................ I 

Propiram (9649) ............................ I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

Racemoramide (9645) .................. I 

Tetrahydrocannabinols (7370) ...... I 

Thebacon (9315) .......................... I 

Thiofentanyl (9835) ....................... I 

Tilidine (9750) ............................... I 

Trimeperidine (9646) .................... I 

1-Phenylcyclohexylamine (7460) .. II 

1-Piperidinocyclohexanecarbonitrile (8603).II 

Alfentanil (9737) ............................ II 

Alphaprodine (9010) ..................... II 

Amobarbital (2125) ....................... II 

Amphetamine (1100) .................... II 

Anileridine (9020) .......................... II 

Bezitramide (9800) ....................... II 

Carfentanil (9743) ......................... II 

Codeine (9050) ............................. II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Dihydrocodeine (9120) ................. II 

Dihydroetorphine (9334) ............... II 

Diphenoxylate (9170) .................... II 

Ethylmorphine (9190) ................... II 

Etorphine Hcl (9059) ..................... II 

Fentanyl (9801) ............................. II 

Glutethimide (2550) ...................... II 

Hydrocodone (9193) ..................... II 

Hydromorphone (9150) ................. II 

Isomethadone (9226) .................... II 

Levo-alphacetylmethadol (9648) .. II 

Levomethorphan (9210) ............... II 

Levorphanol (9220) ....................... II 

Lisdexamfetamine (1205) ............. II 

Meperidine (9230) ......................... II 

Meperidine intermediate-A (9232) II 

Meperidine intermediate-B (9233) II 

Meperidine intermediate-C (9234) II 

Metazocine (9240) ........................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Methamphetamine (1105) ............. II 

Methylphenidate (1724) ................ II 

Metopon (9260) ............................ II 

Moramide intermediate (9802) ..... II 

Morphine (9300) ........................... II 

Nabilone (7379) ............................ II 

Opium, raw (9600) ........................ II 

Opium extracts (9610) .................. II 

Drug Schedule 

Opium fluid extract (9620) ............ II 

Opium tincture (9630) ................... II 

Opium, granulated (9640) ............. II 

Oxycodone (9143) ........................ II 

Oxymorphone (9652) .................... II 

Pentobarbital (2270) ..................... II 

Phenazocine (9715) ...................... II 

Phencyclidine (7471) .................... II 

Phenmetrazine (1631) .................. II 

Phenylacetone (8501) ................... II 

Piminodine (9730) ......................... II 

Powdered opium (9639) ............... II 

Racemethorphan (9732) ............... II 

Racemorphan (9733) .................... II 

Remifentanil (9739) ...................... II 

Secobarbital (2315) ...................... II 

Sufentanil (9740) .......................... II 

Thebaine (9333) ........................... II 

The company plans to import small 

quantities of the listed controlled 

substances for the National Institute on 

Drug Abuse (NIDA) for research 

activities. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Research Triangle Institute to import the 

basic classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated 

Research Triangle Institute to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: July 29, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–17966 Filed 8–5–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated March 19, 2008 and 

published in the Federal Register on 

March 28, 2008, (73 FR 16719), Sigma 

Aldrich Research Biochemicals, Inc., 4–

3 Strathmore Road, Natick, 

Massachusetts 01760–2447, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

Aminorex (1585) ........................... I 

Alpha-ethyltryptamine (7249) ....... I 

Lysergic acid diethylamide (7315) I 

Tetrahydrocannabinols (7370) ..... I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

N-Hydroxy-3,4-methylenedioxyamphetamine (7402).I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4-Methylenedioxymethamphetamine (MDMA) (7405).I 

1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470).I 

1-Benzylpiperazine (BZP) (7493) I 

Heroin (9200) ............................... I 

Normorphine (9313) ..................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Nabilone (7379) ............................ II 

1-Phenylcyclohexylamine (7460) II 

Phencyclidine (7471) .................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Diprenorphine (9058) ................... II 

Ecgonine (9180) ........................... II 

Levomethorphan (9210) ............... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Metazocine (9240) ........................ II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Levo-alphacetylmethadol (9648) .. II 

Carfentanil (9743) ......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

reference standards. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Sigma Aldrich Research Biochemicals, 

Inc. to manufacture the listed basic 

classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated Sigma 

Aldrich Research Biochemicals, Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

mstockstill on PROD1PC66 with NOTICES

45784 Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: July 30, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–18065 Filed 8–5–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 3, 2008, 

Chemic Laboratories, Inc., 480 Neponset 

Street, Building 7, Canton, 

Massachusetts 02021, made application 

by renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of Cocaine (9041), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to manufacture 

small quantities of the above listed 

controlled substance for distribution to 

its customers for the purpose of 

research. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than October 6, 2008. 

Dated: July 28, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–17955 Filed 8–5–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 28, 2008, 

Chattem Chemicals Inc., 3801 St. Elmo 

Avenue, Building 18, Chattanooga, 

Tennessee 37409, made application by 

renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

4-Methoxyamphetamine (7411) .... I 

Difenoxin (9168) ........................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............. II 

Methylphenidate (1724) ................ II 

Pentobarbital (2270) ..................... II 

Codeine (9050) ............................. II 

Oxycodone (9143) ........................ II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ......................... II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Noroxymorphone (9668) ............... II 

Alfentanil (9737) ............................ II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................. II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than October 6, 2008. 

Dated: July 29, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–17961 Filed 8–5–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 3, 2008, 

Cambridge Isotope Lab, 50 Frontage 

Road, Andover, Massachusetts 01810, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) as a bulk manufacturer of 

Morphine (9300), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to utilize small 

quantities of the listed controlled 

substance in the preparation of 

analytical standards. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than October 6, 2008. 

Dated: July 29, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–17962 Filed 8–5–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 28, 2008, 

Boehringer Ingelheim Chemicals, Inc., 

2820 N. Normandy Drive, Petersburg, 

Virginia 23805, made application by 

renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of the basic classes of 

controlled substances listed in schedule 

II: 

Drug Schedule 

Amphetamine (1100) .................... II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Methadone (9250) ........................ II 

mstockstill on PROD1PC66 with NOTICES